IP Library › Granted Patent US 12,358,983
Granted Patent B2
US 12,358,983 · App. 16/342,645 · Granted Jul 15, 2025

Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof

Inventors: Jan Endell (Munich, DE); Konstantin Petropoulos (Munich, DE); Peter Kelemen (Munich, DE); Rainer Boxhammer (Aying, DE); Markus Rückert (Kottgeisering, DE)
Assignee: Incyte Corporation
C07K16/2803A61K9/0019A61K31/496A61K39/395A61P35/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,983
App. No.
16/342,645
Granted
Jul 15, 2025
Kind
B2
Abstract

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

Claims (20)

1. A method for treatment of chronic lymphocytic leukemia, acute lymphoblastic leukemia or non-Hodgkin's lymphoma, said method comprising administering to a human subject with chronic lymphocytic leukemia, acute lymphoblastic leukemia or non-Hodgkin's lymphoma a therapeutically effective amount of a combination comprising an antibody specific for CD19 wherein said antibody comprises an HCDR1 region comprising sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising sequence MQHLEYPIT (SEQ ID NO: 6) and venetoclax.

2. The method of claim 1 , wherein the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue lymphoma, marginal zone lymphoma, diffuse large B cell lymphoma, Burkitt's lymphoma, and mantle cell lymphoma.

3. The method according to claim 1 , wherein the antibody has ADCC activity.

4. The method according to claim 1 , wherein the antibody comprises a variable heavy chain comprising the sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWG QGTLVTVSS (SEQ ID NO: 10) and a variable light chain comprising the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR MSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

5. The method according to claim 1 , wherein the antibody comprises a heavy chain constant domain comprising the sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFP PKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLT WHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL HNHYTQKSLSLSPGK (SEQ ID NO: 12).

6. The method according to claim 1 , wherein the antibody comprises a light chain constant domain comprising the sequence RTVAAPSVFI FPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).

7. The method according to claim 1 , wherein said antibody specific for CD19 and venetoclax are administered separately.

8. The method according to claim 1 , wherein venetoclax is administered prior to administration of the antibody specific for CD19.

9. The method according to claim 1 , wherein said antibody specific for CD19 and venetoclax are administered simultaneously.

10. The method according to claim 1 , wherein said antibody specific for CD19 and venetoclax are administered at a time where both drugs are active in the subject at the same time.

11. The method according to claim 1 wherein said antibody is administered at 11 mg/kg/injection or more.

12. The method according to claim 1 , wherein the human subject has chronic lymphocytic leukemia.

13. The method according to claim 1 , wherein the human subject has acute lymphoblastic leukemia.

14. The method according to claim 1 , wherein the human subject has non- Hodgkin's lymphoma.

15. The method according to claim 12 , wherein the antibody comprises a variable heavy chain comprising the sequence EVOLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGT KYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTL VTVSS (SEQ ID NO:10) and a variable light chain comprising the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL NSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

16. The method according to claim 15 , wherein the antibody comprises a heavy chain constant domain comprising the sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:12) and a light chain constant domain comprising the sequence RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:13).

17. The method according to claim 13 , wherein the antibody comprises a variable heavy chain comprising the sequence EVOLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGT KYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTL VTVSS (SEQ ID NO:10) and a variable light chain comprising the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL NSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

18. The method according to claim 17 , wherein the antibody comprises a heavy chain constant domain comprising the sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:12) and a light chain constant domain comprising the sequence RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:13).

19. The method according to claim 14 , wherein the antibody comprises a variable heavy chain comprising the sequence EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGT KYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTL VTVSS (SEQ ID NO:10) and a variable light chain comprising the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNL NSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

20. The method according to claim 19 , wherein the antibody comprises a heavy chain constant domain comprising the sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQF NSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSR EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:12) and a light chain constant domain comprising the sequence RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:13).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2024
From: MORPHOSYS AG; MORPHOSYS US INC.
To: INCYTE CORPORATION
Reel/Frame 066645/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2019
From: ENDELL, JAN; KELEMEN, PETER; BOXHAMMER, RAINER; PETROPOULOS, KONSTANTIN; RUECKERT, MARKUS
To: MORPHOSYS AG.
Reel/Frame 048912/0961 →
Priority Claims (1)
EP 16196184 · Oct 28, 2016 · regional
Continuity (1)
Related Publication 20190241656A1 · Aug 8, 2019
References Cited (131)
US 4708871A · Geysen · 1987 [cited by applicant]
US 5686072A · Uhr et al. · 1997 [cited by applicant]
US 7109304B2 · Hansen et al. · 2006 [cited by applicant]
US 7514444B2 · Honigberg et al. · 2009 [cited by applicant]
US 7902338B2 · Hansen et al. · 2011 [cited by applicant]
US 7968687B2 · McDonagh et al. · 2011 [cited by applicant]
US 8063187B2 · Chu · 2011 [cited by examiner]
US 8097703B2 · Rao-Naik et al. · 2012 [cited by applicant]
US 8323653B2 · Damschroder et al. · 2012 [cited by applicant]
US 8524867B2 · Bernett et al. · 2013 [cited by applicant]
US 8546399B2 · Bruncko et al. · 2013 [cited by applicant]
US 8549399B2 · Bruncko et al. · 2013 [cited by applicant]
US 8679492B2 · Blein et al. · 2014 [cited by applicant]
US 8691952B2 · Super et al. · 2014 [cited by applicant]
US 8754090B2 · Buggy et al. · 2014 [cited by applicant]
US 9174982B2 · Bruncko et al. · 2015 [cited by applicant]
US 10617691B2 · Endell et al. · 2020 [cited by applicant]
US 20070154473A1 · Super et al. · 2007 [cited by applicant]
US 20100068136A1 · Hansen et al. · 2010 [cited by applicant]
US 20100128586A1 · Wu et al. · 2010 [cited by applicant]
US 20120128586A1 · Calissano et al. · 2012 [cited by applicant]
US 20150158846A1 · Crawford · 2015 [cited by examiner]
US 20150283178A1 · June · 2015 [cited by examiner]
US 20170137516A1 · Foster et al. · 2017 [cited by applicant]
US 20180153892A1 · Endell et al. · 2018 [cited by applicant]
US 20190195879A1 · Endell et al. · 2019 [cited by applicant]
US 20210130461A1 · Endell et al. · 2021 [cited by applicant]
US 20210154209A1 · Baskin-Bay et al. · 2021 [cited by applicant]
US 20210292410A1 · Kelemen et al. · 2021 [cited by applicant]
CN 103703027 · 2014 [cited by applicant]
CN 103732252 · 2014 [cited by applicant]
CN 109890418 · 2019 [cited by applicant]
JP 2014525925 · 2014 [cited by applicant]
JP 2014525926 · 2014 [cited by applicant]
WO 2002022212 · 2002 [cited by applicant]
WO WO2003048731 · 2003 [cited by applicant]
WO 2005012493 · 2005 [cited by applicant]
WO 2007002223 · 2007 [cited by applicant]
WO 2007076950 · 2007 [cited by applicant]
WO 2008022125 · 2008 [cited by applicant]
WO WO2008022152 · 2008 [cited by applicant]
WO 2008031056 · 2008 [cited by applicant]
WO 2008150494 · 2008 [cited by applicant]
WO 2009052431 · 2009 [cited by applicant]
WO 2010053716 · 2010 [cited by applicant]
WO 2010095031 · 2010 [cited by applicant]
WO 2010151341 · 2010 [cited by applicant]
WO 2011147834 · 2011 [cited by applicant]
WO 2012010561 · 2012 [cited by applicant]
WO 2012010562 · 2012 [cited by applicant]
WO 2012156455 · 2012 [cited by applicant]
WO 2013024095 · 2013 [cited by applicant]
WO 2013024097 · 2013 [cited by applicant]
WO 2015130585 · 2015 [cited by applicant]
WO WO2015195498 · 2015 [cited by applicant]
WO WO2016064929 · 2016 [cited by applicant]
WO 2016130902 · 2016 [cited by applicant]
WO WO2016188935 · 2016 [cited by applicant]
WO WO2016189014 · 2016 [cited by applicant]
WO WO2017004532 · 2017 [cited by applicant]
WO WO2017032679 · 2017 [cited by applicant]
WO WO2017207574 · 2017 [cited by applicant]
WO WO2018002031 · 2018 [cited by applicant]
WO WO2018220040 · 2018 [cited by applicant]
WO WO2019113301 · 2019 [cited by applicant]
WO WO2020055040 · 2020 [cited by applicant]
WO WO2020225196 · 2020 [cited by applicant]
WO WO2021084062 · 2021 [cited by applicant]
WO WO2021084063 · 2021 [cited by applicant]
WO WO2021084064 · 2021 [cited by applicant]
WO WO2021259902 · 2021 [cited by applicant]
WO WO2022117799 · 2022 [cited by applicant]
WO WO2023118395 · 2023 [cited by applicant]
Anderson et al. “Expression of Human B cell—Associated Antigens on Leukemias and Lymphomas: A Model of Human B Cell Differentiation” Blood 1984 63:1424-1433. [cited by applicant]
Grossbard et al. “Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma” Br. J. Haematol 1998 102:509-515. [cited by applicant]
Kalos et al. “T cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia” Science Translational Medicine 2011 3(95):1-21. [cited by applicant]
Karlsson et al. “Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy” Cancer Gene Therapy 2013 20:386-393. [cited by applicant]
Loken et al. “Flow Cyotmetric Analysis of Human Bone Marrow: I. Normal Erythroid Development” Blood 1987 70:1316-1324. [cited by applicant]
Nadler et al. “B4, A Human B Lymphocyte—associated Antigen Expressed on Normal Mitogen-Activated, and Malignant B Lymphocytes” J. Immunol. 1983 131:244-250. [cited by applicant]
Sadelain et al. :The promise and potential pitfalls of chimeric antigen receptors Current Opinion in Immunology 2009 21(2) :215-223. [cited by applicant]
Scheuermann et al. “CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy” Leukemia and Lymphoma 1995 18:385-397. [cited by applicant]
Treon et al. “Expression of Serotherapy Target Antigens in Waldenstrom's Macroglobulinemia: Therapeutic Applications and Considerations” Semin. Oncol 2003 30:248-52. [cited by applicant]
Uckun et al. “Detailed Studies on Expression and Function of CD19 Surface Determinant by Using B43 Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins” Blood, 1988 71:13-29. [cited by applicant]
Extended European Search Report in EP 16196184.2 dated Sep. 14, 2017. [cited by applicant]
Caruana et al., “From Monoclonal Antibodies to Chimeric Antigen Receptors for the Treatment of Human Malignancies,” Semin Oncol., Oct. 2014, 41(5):661-666. [cited by applicant]
Chou et al., “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors,” Adv Enzyme Regul., 1984, 22:27-55. [cited by applicant]
Chou, “Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies,” Pharmacol Rev., 2006, 58:621-681. [cited by applicant]
Clarke, “Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models,” Breast Cancer Research and Treatment, 1997, 46:255-278. [cited by applicant]
Geysen et al., “A priori delineation of a peptide which mimics a discontinuous antigenic determinant,” Mol. Immunol., 1986, 23:709-715. [cited by applicant]
Geysen et al., “Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein,” Proc Natl Acad Sci USA., 1985, 82:178-182. [cited by applicant]
Geysen et al., “Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid,” Proc Natl Acad Sci USA., 1984, 8:3998-4002. [cited by applicant]
Hopp et al., “Prediction of protein antigenic determinants from amino acid sequences,” Proc Natl Acad Sci USA., 1981, 78:3824-3828. [cited by applicant]
Imgt.org, “Human IGH C-REGIONs,” Jun. 16, 2020 [retrieved on Jan. 12, 2021], retrieved from URL <www.imgt.org/IMGTrepertoire/Proteins/protein/human/IGH/IGHC/Hu_IGHCallgen es.html>, 2 pages. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/EP2017/077654, dated Apr. 30, 2019, 6 pages. [cited by applicant]
Jin et al., “Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer,” Cancer Cell Int., 2021, 21:83. [cited by applicant]
Kyte et al., “A simple method for displaying the hydropathic character of a protein,” J Mol Biol., 1982, 157:105-132. [cited by applicant]
Loken et al., “Flow Cytometric Analysis of Human Bone Marrow: I. Normal Erythroid Development,” Blood, Jan. 1987, 69(1):255-263. [cited by applicant]
Ma, “Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study,” Blood, Dec. 3, 2015, 1… [cited by applicant]
Robak et al., “Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia,” Semin Oncol., Apr. 2016, 43(2):280-290. [cited by applicant]
Abou Zahr et al., “Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia,” Expert opinion on pharmacotherapy, 2017, 18(9):857-873. [cited by applicant]
Boxhammer et al., “Activity of The CD19 AntibodyMOR208 in Combination with Ibrutinib, Idelalisib or Venetoclax in Vitro,” EHA Learning Center, 2017, pp. 1-2. [cited by applicant]
Campo et al., “The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications,” Blood, 2011, 117(19):5019-5032. [cited by applicant]
ClinicalTrials.gov [online], “History of Changes for Study: NCT02639910 Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTK,” NCT02639910, Submitted … [cited by applicant]
Clinicaltrials.gov, “A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previousl… [cited by applicant]
Clinicaltrials.gov, “Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia,” NCT02427451, last updat… [cited by applicant]
Dores et al., “Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology,” 2007, 139(5):809-819. [cited by applicant]
Extended European Search Report for the Application No. 17173712.5, dated Oct. 4, 2017, 8 pages. [cited by applicant]
Fischer et al., “Results of the safety run-in phase of CLL14 (BO25323): a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and venetoclax (GDC-0199/ABT-1… [cited by applicant]
Fischer et al., “Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Ra… [cited by applicant]
Hallek et al., “Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1… [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/EP2018/064229, dated Dec. 3, 2019, 8 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/EP2018/064229, dated Apr. 9, 2018, 12 pages. [cited by applicant]
Jagasia et al., “Complications of hematopoietic neoplasms,” Wintrobe's Clinical Hematology, 11th edition, 2003, 2(72):1919-1944. [cited by applicant]
Martens et al., “CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells,” J Immunother Cancer., 2020, 8… [cited by applicant]
Morabito et al., “Promising therapies for the treatment of chronic lymphocytic leukemia,” Expert Opinion on Investigational Drugs, 2015, 24(6):795-807. [cited by applicant]
Shah et al., “Incorporating Novel Targeted and Immunotherapeutic Agents in the Treatment of B-Cell Lymphomas,” Hematologic Malignancies, Mar. 25, 2021, pp. 310-327. [cited by applicant]
Wendtner et al., “Cosmos: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyro… [cited by applicant]
Yang et al., “Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13,” Frontiers In Immunol., Dec. 2020, 11:610696. [cited by applicant]
Office Communication in U.S. Appl. No. 16/615,953, filed Nov. 22, 2019 dated Nov. 26, 2021. [cited by applicant]
Office Communication in U.S. Appl. No. 16/615,953, filed Nov. 22, 2019 dated Apr. 22, 2022. [cited by applicant]
Office Communication in U.S. Appl. No. 16/615,953, filed Nov. 22, 2019 dated Aug. 29, 2022. [cited by applicant]
Office Communication in U.S. Appl. No. 16/615,953, filed Nov. 22, 2019 dated Nov. 9, 2022. [cited by applicant]
Ishioka, “Carcinogenesis and apoptosis of cell,” Japanese Journal of Clinical Medicine, Jan. 2009, 67(S1):77-85 (with machine english abstract). [cited by applicant]
Naoe et al., “Molecule-targeted therapy for malignant lymphoma,” History of Medicine, Jan. 2005, 212(5):383-388 (with machine english abstract). [cited by applicant]
Office Communication in U.S. Appl. No. 16/615,953, filed Nov. 22, 2019 dated Sep. 8, 2023. [cited by applicant]
Office Communication dated Jan. 25, 2024 in U.S. Appl. No. 16/615,953, filed Nov. 22, 2019. [cited by applicant]
Abb Vie Inc., “Venclexta Prescribing Information,” 2016, retrieved from URL<https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s0001bl.pdf>, 25 pages. [cited by applicant]
Extended European Search Report in European Application No. 23190328.7, dated Feb. 5, 2024, 11 pages. [cited by applicant]
Kang et al., “Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy,” Clinical Cancer Research, 2009, 15(4):1126-1132. [cited by applicant]
Staber et al., “Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R Cll Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial),” Blood, 2019, 134(Supp… [cited by applicant]
Horton et al., “Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia,” Cancer Research, Oct. 1, 2008, 68(19):8049-8057. [cited by applicant]